

Dr. David J. Earp steps down as Sienna board member

Melbourne, Australia, 14 November 2019: [Sienna Cancer Diagnostics Ltd \(ASX: SDX\)](#) (“Sienna” or “the Company”), wishes to advise that long standing and highly respected Non-executive Director, David J. Earp, JD, PhD has stepped down effective at the end of today’s Annual General Meeting (AGM).

“It has been my privilege to serve on the Sienna board for the last 7 years. I have greatly appreciated working closely with my colleagues on the board and the whole team at Sienna,” said Dr. Earp. “Over my time on the board, Sienna has progressed from an early stage discovery company through to its first launched product, commercial sales and an ASX listing. And today Sienna stands with a new platform technology from its recent acquisition of Sevident’s technology. That technology promises to open up significant new and large market opportunities for Sienna, including in liquid biopsy and especially in the emerging exosome space. I look forward to seeing the company’s continued progress in the months and years ahead.”

Sienna’s Chairman, Geoff Cumming said, “We are deeply grateful for David’s seven years of service to Sienna; his departure is a loss for the board and the company. He has been a diligent director who has contributed critical analysis on a broad range of issues, offered valuable guidance on matters of governance and delivered great insights in his particular areas of expertise, IP and partnering strategy”.

ENDS

For further information, please contact:

Geoff Cumming, Chairman
Sienna Cancer Diagnostics
gcumming@siennadiagnostics.com.au
+61 3 8288 2141

Tony Di Pietro, CFO & Company Secretary
Sienna Cancer Diagnostics
tdipietro@siennadiagnostics.com.au
+61 3 8288 2141


About Sienna Cancer Diagnostics

Sienna Cancer Diagnostics Ltd. (“the Company”, or “Sienna”) is an Australian medical technology company with operations in the United States and Australia, and distributors for its products in the United States, Europe, Asia and Latin America.

Sienna’s vision is to become a hub for the development and commercialisation of *in-vitro* diagnostic (IVD) tests for the global pathology market. Our mission is to create a portfolio of products to bring to market much needed cancer diagnostic solutions, which will in turn generate additional revenue and long-term growth for Sienna’s shareholders.

Sienna’s strengths lie in the identification, development and commercialisation of novel IVD technologies that satisfy an unmet clinical / market need. Our first product is an antibody-based IVD test to detect the biomarker “hTERT”. Sienna has taken the hTERT test from research, through development and manufacturing, to product registration and sales through a growing network of distribution partners.

The Company intends to fill an important gap in the Australian MedTech ecosystem, by providing a capable, efficient and effective development, manufacturing and commercial launch pathway for IVD technologies sourced from leading universities and research institutions.





As part of this technology expansion strategy, Sienna recently acquired a unique technology for the capture and isolation of target biomarkers in liquid biopsy samples. The sample preparation technology, known as SIEN-NET™, can more accurately and rapidly prepare samples for the liquid biopsy testing of a range of clinically useful biomarkers, including exosomes, lipids, proteins, and other molecular targets of interest.

We are focussed on growing revenues from the hTERT test, increasing market access through new distribution partnerships, commercialisation of the SIEN-NET™ product line, and expanding our product offerings with the addition of new technologies.

